Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibandronic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS known ✓ | P14324 | 19/20 | 0.93 |
| ▸ | GGPS1 | O95749 | 8/20 | 0.93 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.93 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.93 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.93 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.57 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.57 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.57 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ibandronic Acid SCHEMBL28564280 | 1.00 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL1240197 | 1.00 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3415425 | 1.00 | FDPS (0.93) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3624745 | 0.98 | FDPS (0.90) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL163394 | 0.98 | FDPS (0.90) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3630021 | 0.98 | FDPS (0.90) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3628878 | 0.98 | FDPS (0.90) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL3419518 | 0.98 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL1579193 | 0.98 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A | |
| Ibandronic Acid SCHEMBL1030766 | 0.98 | FDPS (0.97) | FDPSGGPS1AGTR1OPRM1PDE3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1561 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| CN-119395194-A | Method for determining content of genotoxic impurities in ibandronate sodium | 石家庄凯达生物工程有限公司 | 2025-02-07 | — | — | CN | claimed |
| CN-119178832-A | Gas chromatography for determining amine impurities in ibandronate sodium | 石家庄凯达生物工程有限公司 | 2024-12-24 | — | — | CN | claimed |
| CN-118772015-A | Ibandronate sodium intermediate I and preparation method thereof | 上海旭东海普药业有限公司 | 2024-10-15 | — | — | CN | claimed |
| CN-118649295-A | Degradable drug-loaded fiber membrane for vertebral body saccule and preparation process thereof | 山东百多安医疗器械股份有限公司 | 2024-09-17 | — | — | CN | claimed |
| CN-115887783-B | Polyester-based composite microsphere with calcium-phosphorus-containing layer on surface and preparation method and application thereof | 广东省科学院生物与医学工程研究所 | 2024-08-23 | — | — | CN | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-118501305-A | Determination method for dissolution rate of bisphosphonate solid preparation in phosphate medium | 北京诺康达医药科技股份有限公司 | 2024-08-16 | — | — | CN | claimed |
| EP-1251857-B1 | PHARMACEUTICAL PARENTERAL COMPOSITION CONTAINING A BISPHOSPHONATE | HOFFMANN LA ROCHE (CH) | 2006-02-22 | — | — | EP | claimed |
| WO-2006002348-A2 | SOLID AND CRYSTALLINE IBANDRONIC ACID | TEVA PHARMACEUTICAL INDUSTIES LTD. (IL) | 2006-01-05 | — | — | WO | claimed |
| US-20050075319-A1 | Method of treatment using bisphosphonic acid | BAUSS FRIEDER (DE) | 2005-04-07 | — | — | US | claimed |
| US-6770289-B2 | FOR EASY ADMINISTRATION WITHOUT THE SIDE EFFECTS | RIDERWAY CORPORATION (PA) | 2004-08-03 | — | — | US | claimed |
| CN-1151161-C | Nitrate salts of drugs | ƿ�ӻ��� | 2004-05-26 | — | — | CN | claimed |
| EP-1251857-A1 | PHARMACEUTICAL PARENTERAL COMPOSITION CONTAINING A BISPHOSPHONATE | F. HOFFMANN-LA ROCHE AG (CH) | 2002-10-30 | — | — | EP | claimed |
| US-20020142997-A1 | Liquid pharmaceutical composition for treating bone diseases | RIDERWAY CORPORATION | 2002-10-03 | — | — | US | claimed |
| EP-1228761-A2 | Liquid pharmaceutical composition for treating bone diseases | Riderway Corporation (PA) | 2002-08-07 | — | — | EP | claimed |
| CN-1310721-A | Medicine nitrate salts | NICOX SA (FR) | 2001-08-29 | — | — | CN | claimed |
| WO-2001052859-A1 | PHARMACEUTICAL PARENTERAL COMPOSITION CONTAINING A BIPHOSPHONATE | F. HOFFMANN-LA ROCHE AG (CH) | 2001-07-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | FDPS 2271/4885GGPS1 797/4885AGTR1 3705/4885 |
| US-20050075319-A1 | Method of treatment using bisphosphonic acid | SOST, BPGM, PTH1R | FDPS 436/4885GGPS1 185/4885AGTR1 1785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.